AstraZeneca rejects Pfizer bid as inadequate
May 02, 2014 at 06:36 AM EDT
AstraZeneca says an improved takeover offer from Pfizer worth more than $106 billion substantially undervalues the company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|